Home » Stocks » Intellia Therapeutics

Intellia Therapeutics, Inc. (NTLA)

Stock Price: $19.25 USD 1.44 (8.09%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $19.56 +0.31 (1.61%) Aug 3, 6:15 PM

Stock Price Chart

Key Info

Market Cap 989.07M
Revenue (ttm) 45.59M
Net Income (ttm) -109.40M
Shares Out 58.65M
EPS (ttm) -2.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $19.25
Previous Close $17.81
Change ($) 1.44
Change (%) 8.09%
Day's Open 18.28
Day's Range 17.96 - 19.68
Day's Volume 911,137
52-Week Range 9.18 - 25.56

More Stats

Market Cap 989.07M
Enterprise Value 763.18M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 58.65M
Float 45.14M
EPS (basic) -2.26
EPS (diluted) -2.25
FCF / Share -2.50
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.18M
Short Ratio 11.16
Short % of Float 25.50%
Beta 1.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 21.70
PB Ratio 4.43
Revenue 45.59M
Operating Income -115.61M
Net Income -109.40M
Free Cash Flow -126.44M
Net Cash 225.90M
Net Cash / Share 4.40
Gross Margin -143.27%
Operating Margin -253.60%
Profit Margin -240.00%
FCF Margin -277.36%
ROA -21.93%
ROE -42.73%
ROIC -42.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 6
Overweight 2
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$28.65*
(48.83% upside)
Low
16.0
Current: $19.25
High
57.5
Target: 28.65
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue43.1030.4326.1216.486.04
Revenue Growth41.63%16.53%58.49%172.65%-
Gross Profit43.1030.4326.1216.486.04
Operating Income-106-90.87-69.56-32.16-13.41
Net Income-99.53-85.34-67.54-31.63-12.40
Shares Outstanding47.2543.0736.0122.220.24
Earnings Per Share-2.11-1.98-1.88-1.42-51.02
Operating Cash Flow-103-61.26-65.2836.11-1.76
Capital Expenditures-6.79-6.23-10.09-6.17-2.55
Free Cash Flow-110-67.48-75.3729.94-4.32
Cash & Equivalents28031434127375.82
Total Debt18.38----
Net Cash / Debt26131434127375.82
Assets33434737629982.14
Liabilities64.4069.4075.6489.13103
Book Value270278301210-21.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intellia Therapeutics, Inc.
Country United States
Employees 270
CEO John M. Leonard

Stock Information

Ticker Symbol NTLA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NTLA
IPO Date May 6, 2016

Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.